Merve Oyken

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Top Venues

Journal of medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Yuqing Jia, Merve Oyken, Robbert Q Kim, Rayman T N Tjokrodirijo, Arnoud H de Ru, Antonius P A Janssen, Stephan M Hacker, Peter A van Veelen, Paul P Geurink, Aysegul Sapmaz
Development of Inhibitors, Probes, and PROTAC Provides a Complete Toolbox to Study PARK7 in the Living Cell. Journal of medicinal chemistry 67 (10) (2024)
Yuqing Jia, Merve Oyken, Robbert Q Kim, Rayman T N Tjokrodirijo, Arnoud H de Ru, Antonius P A Janssen, Stephan M Hacker, Peter A van Veelen, Paul P Geurink, Aysegul Sapmaz
Development of Inhibitors, Probes, and PROTAC Provides a Complete Toolbox to Study PARK7 in the Living Cell. Journal of medicinal chemistry 67 (10) (2024)
Yuqing Jia, Merve Oyken, Robbert Q Kim, Rayman T N Tjokrodirijo, Arnoud H de Ru, Antonius P A Janssen, Stephan M Hacker, Peter A van Veelen, Paul P Geurink, Aysegul Sapmaz
Development of Inhibitors, Probes, and PROTAC Provides a Complete Toolbox to Study PARK7 in the Living Cell. Journal of medicinal chemistry 67 (10) (2024)
Yuqing Jia, Merve Oyken, Robbert Q Kim, Rayman T N Tjokrodirijo, Arnoud H de Ru, Antonius P A Janssen, Stephan M Hacker, Peter A van Veelen, Paul P Geurink, Aysegul Sapmaz
Development of Inhibitors, Probes, and PROTAC Provides a Complete Toolbox to Study PARK7 in the Living Cell. Journal of medicinal chemistry 67 (10) (2024)
Yuqing Jia, Merve Oyken, Robbert Q Kim, Rayman T N Tjokrodirijo, Arnoud H de Ru, Antonius P A Janssen, Stephan M Hacker, Peter A van Veelen, Paul P Geurink, Aysegul Sapmaz
Development of Inhibitors, Probes, and PROTAC Provides a Complete Toolbox to Study PARK7 in the Living Cell. Journal of medicinal chemistry (2024)
Esra Cicek, Ayca Circir, Merve Oyken, Ozge Akbulut-Caliskan, Didem Naz Dioken, Sezen Guntekin Ergun, Rengul Cetin-Atalay, Aysegul Sapmaz, Huib Ovaa, Özgür Sahin, Ayse Elif Erson-Bensan
EGF-SNX3-EGFR axis drives tumor progression and metastasis in triple-negative breast cancers. Oncogene (2021)